Project Grant R01CA276946
Award Date
12/1/22
Completion Date
11/30/27
Dollars Obligated
$1.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $684,877 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct a multi-scale analysis of the Bacillus Calmette-Guerin (BCG) resistant tumor microenvironment in non-muscle invasive bladder cancer. The 5-year project aims to generate a comprehensive molecular atlas of the bladder tumor microenvironment, leveraging single-cell sequencing and spatial transcriptomics, to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This $168,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to examine risk factors and develop prediction models for multiple recurrences of non-muscle invasive bladder cancer (NMIBC). The primary objectives are to: 1) analyze associations between demographic, lifestyle, social, tumor, comorbidity, and treatment factors and risks of first and multiple NMIBC recurrences, and 2) develop and...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,437 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to enhance the immunogenicity of nectin-4 targeted therapy for the treatment of aggressive bladder cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical...
This Project Grant award of $514,582, provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of North Carolina at Chapel Hill, supports research on the role of APOBEC3 enzymes in bladder cancer initiation, progression, and treatment resistance. The research aims to gain a better understanding of how APOBEC3 promotes squamous differentiation in bladder tumors and explore whether co-inhibition of the IL1A pathway can be leveraged to reverse...
This federal Project Grant award of $654,090.00 from the Defense Health Agency is for the "CANCER CELL INTRINSIC REGULATION OF ANTIBODY-DRUG CONJUGATE TARGETS IN BLADDER CANCER" research project at Pennsylvania State University's Milton S. Hershey Medical Center. The research, which runs from September 30, 2024 to September 29, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to investigate innovative approaches to cancer...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...